ARS Pharmaceuticals Statistics
Want to see SPRY full AI Analyst Report?
ARS Pharmaceuticals (SPRY) Stock Statistics & Valuation Metrics
Total Valuation
ARS Pharmaceuticals has a market cap or net worth of $391.06M. The enterprise value is $413.10M.
- Market Cap
- $391.06M
- Enterprise Value
- $413.10M
Share Statistics
ARS Pharmaceuticals has 100,528,400 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 100,528,400
- Owned by Insiders
- 26.89%
- Owned by Institutions
- 35.57%
Financial Efficiency
ARS Pharmaceuticals’s return on equity (ROE) is -1.50 and return on invested capital (ROIC) is -62.17%.
- Return on Equity (ROE)
- -1.50
- Return on Assets (ROA)
- -0.52
- Return on Invested Capital (ROIC)
- -62.17%
- Return on Capital Employed (ROCE)
- -0.62
- Revenue Per Employee
- 415.16K
- Profits Per Employee
- -843.83K
- Employee Count
- 203
- Asset Turnover
- 0.26
- Inventory Turnover
- 2.44
Valuation Ratios
The current PE Ratio of ARS Pharmaceuticals is -1.93. ARS Pharmaceuticals’s PEG ratio is 0.02.
- PE Ratio
- -1.93
- PS Ratio
- 3.20
- PB Ratio
- -32.44
- Price to FCF
- -2.14
- Price to Operating Cash Flow
- -2.12
- PEG Ratio
- 0.02
Income Statement
In the last 12 months, ARS Pharmaceuticals had revenue of 84.28M and earned -171.30M in profits. Earnings per share was -1.74.
- Revenue
- 84.28M
- Gross Profit
- 63.85M
- Operating Income
- -179.45M
- Pretax Income
- -171.38M
- Net Income
- -171.30M
- EBITDA
- -167.41M
- Earnings Per Share (EPS)
- -1.74
Cash Flow
In the last 12 months, operating cash flow was -183.07M and capital expenditures 0, giving a free cash flow of -183.07M billion.
- Operating Cash Flow
- -183.07M
- Free Cash Flow
- -183.07M
- Free Cash Flow per Share
- -1.84
Dividends & Yields
ARS Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -46.81%
- Earnings Yield
- -51.54%
Stock Price Statistics
- Beta
- 1.40
- 52-Week Price Change
- -53.75%
- 50-Day Moving Average
- 4.08
- 200-Day Moving Average
- 6.99
- Relative Strength Index (RSI)
- 53.06
- Average Volume (3m)
- 1.78M
Important Dates
ARS Pharmaceuticals upcoming earnings date is Mar 25, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Mar 25, 2027
- Ex-Dividend Date
- ―
Financial Position
ARS Pharmaceuticals as a current ratio of 7.28, with Debt / Equity ratio of 84.35%
- Current Ratio
- 7.28
- Quick Ratio
- 7.06
- Debt to Market Cap
- 0.08
- Net Debt to EBITDA
- -0.33
- Interest Coverage Ratio
- -69.05
Taxes
In the past 12 months, ARS Pharmaceuticals has paid -80.00K in taxes.
- Income Tax
- -80.00K
- Effective Tax Rate
- 0.00
Enterprise Valuation
ARS Pharmaceuticals EV to EBITDA ratio is -2.95, with an EV/FCF ratio of -3.07.
- EV to Sales
- 4.61
- EV to EBITDA
- -2.95
- EV to Free Cash Flow
- -3.07
- EV to Operating Cash Flow
- -3.07
Balance Sheet
ARS Pharmaceuticals has $138.35M in cash and marketable securities with $197.01M in debt, giving a net cash position of -$58.66M billion.
- Cash & Marketable Securities
- $138.35M
- Total Debt
- $197.01M
- Net Cash
- -$58.66M
- Net Cash Per Share
- -$0.58
- Tangible Book Value Per Share
- -$0.26
Margins
Gross margin is 73.45%, with operating margin of -161.50%, and net profit margin of -163.64%.
- Gross Margin
- 73.45%
- Operating Margin
- -161.50%
- Pretax Margin
- -163.71%
- Net Profit Margin
- -163.64%
- EBITDA Margin
- -156.24%
- EBIT Margin
- -157.59%
Analyst Forecast
The average price target for ARS Pharmaceuticals is $17.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $17.33
- Price Target Upside
- 345.59% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 3
- Revenue Growth Forecast
- -14.45%
- EPS Growth Forecast
- -148.35%
Scores
- Smart Score
- 2
- AI Score
- 45

